mitoguazone and Carcinoma--Renal-Cell

A trial of melphalan and methyl-gag was undertaken in 16 patients with metastatic renal cell carcinoma. Among 14 evaluable patients, 6 had stabilization of disease. No significant responses were observed. While both drugs have produced occasional responses in renal cancer, their combination shows no therapeutic advantage.

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Melphalan; Middle Aged; Mitoguazone

Mitoguazone (methylglyoxal-bis(guanyl-hydrazone), MGBG) was studied by its first-pass mechanism in both cancer patients and experimental cancer models. It appears from the study that 90% of MGBG is cleared from the plasma within minutes. 24-h recovery in the urine, however, did not exceed 16% so that 84% of the drug seems to be bound to subcellular compartments. Tissue levels of MGBG in the normal prostate ranged higher than in experimental prostate cancer type 3327 M/G, i.e. enhanced clearance from cancer tissues: polyamine biosynthetic enzymes ornithine decarboxylase as well as S-adenosylmethionine decarboxylase are contrarily affected by MGBG.

Topics: Adenocarcinoma; Adenosylmethionine Decarboxylase; Animals; Carcinoma, Renal Cell; Cell Line; Cells, Cultured; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Parenteral; Kidney Neoplasms; Male; Mice; Mice, Inbred Strains; Mitoguazone; Ornithine Decarboxylase; Prostatic Neoplasms; Rats; Rats, Inbred Strains; Tissue Distribution